1. Home
  2. HTCR vs GANX Comparison

HTCR vs GANX Comparison

Compare HTCR & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTCR
  • GANX
  • Stock Information
  • Founded
  • HTCR 2009
  • GANX 2017
  • Country
  • HTCR Japan
  • GANX United States
  • Employees
  • HTCR N/A
  • GANX N/A
  • Industry
  • HTCR EDP Services
  • GANX Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTCR Technology
  • GANX Health Care
  • Exchange
  • HTCR Nasdaq
  • GANX Nasdaq
  • Market Cap
  • HTCR 48.1M
  • GANX 41.9M
  • IPO Year
  • HTCR 2022
  • GANX 2021
  • Fundamental
  • Price
  • HTCR $1.34
  • GANX $2.27
  • Analyst Decision
  • HTCR
  • GANX Strong Buy
  • Analyst Count
  • HTCR 0
  • GANX 5
  • Target Price
  • HTCR N/A
  • GANX $7.60
  • AVG Volume (30 Days)
  • HTCR 129.1K
  • GANX 218.6K
  • Earning Date
  • HTCR 04-07-2025
  • GANX 03-25-2025
  • Dividend Yield
  • HTCR 2.98%
  • GANX N/A
  • EPS Growth
  • HTCR N/A
  • GANX N/A
  • EPS
  • HTCR 0.23
  • GANX N/A
  • Revenue
  • HTCR $30,290,930.00
  • GANX N/A
  • Revenue This Year
  • HTCR $53.30
  • GANX N/A
  • Revenue Next Year
  • HTCR N/A
  • GANX N/A
  • P/E Ratio
  • HTCR $5.76
  • GANX N/A
  • Revenue Growth
  • HTCR 47.63
  • GANX N/A
  • 52 Week Low
  • HTCR $0.55
  • GANX $0.89
  • 52 Week High
  • HTCR $3.38
  • GANX $5.19
  • Technical
  • Relative Strength Index (RSI)
  • HTCR 42.19
  • GANX 47.71
  • Support Level
  • HTCR $1.41
  • GANX $2.30
  • Resistance Level
  • HTCR $1.60
  • GANX $2.81
  • Average True Range (ATR)
  • HTCR 0.13
  • GANX 0.25
  • MACD
  • HTCR -0.01
  • GANX -0.03
  • Stochastic Oscillator
  • HTCR 2.50
  • GANX 35.33

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. It provides software through two business units. The first business unit includes a customer experience management business that has been in existence for 12 years. The customer experience management platform includes marketing, sales, service and content management systems, as well as other tools and integrations, that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, its DX division, is a digital transformation business that provides customers with robotics process automation, process mining and task mining to accelerate the digital transformation of enterprises.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.

Share on Social Networks: